Revaclear Dialyzer

The Revaclear Dialyzer Difference

Optimizing high-flux performance

The Revaclear dialyzer is designed to optimize clearance with a smaller surface area.¹

Sterilization and priming

The Revaclear dialyzer uses steam sterilization; it is never sterilized by E-beam or EtO. At a minimum, 300 mL of saline would be required for priming.^2,3

Safety and efficiency in mind

The relatively compact surface area and uniform flow characteristics of the Revaclear dialyzer minimizes stagnant areas of blood—potentially reducing clotting—and provides easy and complete rinseback of blood after treatments.¹

Advantages of the Revaclear Dialyzer

The Poracton membrane (PAES/PVP, BPA-Free) provides effective permeability with minimal resistance to diffusion.^4-6

Removes small and conventional middle molecules during hemodialysis therapy at a rate equivalent to that of a dialyzer with a 22% larger surface area.⁷

May help manage patient risks by reducing exposure of blood, potentially reducing clotting and inflammation.¹

Optimizing performance⁷ with safety and biocompatibility in mind.

Introducing the Revaclear 500 Dialyzer

The 2.1 m² surface area of the Revaclear 500 dialyzer may help even more patients achieve adequacy without impacting treatment times.^2,3

The Revaclear dialyzer may enable cost savings through reduced ESA

In a large-scale, retrospective, observational study of US HD patients (N ~37,500), the Revaclear 300 and 400 dialyzers were associated with lower doses of erthropoiesis-stimulating agents (ESAs) used per session compared with Optiflux dialyzers.⁸The median difference was 275 fewer units of ESAs, which could lead to $4.39 in savings per treatment, or $660 annually.*^9-11

_{*This is a conservative average calculated over 12 months.}

$4.39

Estimated savings for each HD session by reducing per-session ESA dose by 275 units^9-11

$660

Estimated annual ESA savings for one patient receiving 3 dialysis sessions per week*^9-11

Learn more about the Revaclear Dialyzer series

Read more about how the Revaclear series enhances the safety and biocompatibility of high-flux treatments for patients.

Download brochure Download datasheet

Important Safety Information

INDICATION

Revaclear 300, 400, and 500 dialyzers are indicated for treatment of chronic or acute renal failure by Hemodialysis or Hemodiafiltration.

For single use only.

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operators Manual or Instructions for Use.

Vantive, AK 98, Polyflux, Poracton, Revaclear and Theranova are trademarks of Vantive Health LLC or its affiliates.

References

Vantive Health LLC. Revaclear dialyzers: Optimized for efficient high-flux HD treatments, May 2013.
Vantive Health LLC. Revaclear 300 400 IFU, 2019.
Vantive Health LLC. Revaclear 300 400 500 IFU, 2022.
Ronco C, Crepaldi C, Brendolan A, et al. Evolution of synthetic membranes for blood purification: the case of the Polyflux family. Nephrol Dial Transplant. 2003;18(Suppl 7):vii10-20.
Ward R, Ouseph R. Modification of membrane characteristics allows a reduction in dialyzer membrane area without loss of performance. Abstract SA-PO510, presented at the 40th American Society of Nephrology (ASN) Congress. San Francisco, USA, 2007.
Bhimani JP, Ouseph R, Ward RA. Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and beta2-microglobulin during clinical haemodialysis. Nephrol Dial Transplant. 2010;25:3990–3995.
Mauric A, et al. Poster SP401, presented at 50th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress. Istanbul (Turkey), 2013.
Sibbel S, Hunt A, Laplante S, Beck W, Gellens M, Brunelli SM. Comparative effectiveness of dialyzers: a longitudinal, propensity score-matched study of incident hemodialysis patients. ASAIO J. 62(5):613-22.
Vantive Health LLC. Final Study Report, December 2014. Data on file.
Micromedex Solutions. EPOGEN (Epoetin alfa) RED BOOK Online Product Details. 2016.
Vantive Health LLC. Cost Calculation. Assumes 150 dialysis sessions per patient per year. Data on file.